JAJeffrey A. Alten

Jeffrey A. Alten

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeffrey A. Alten has a total of 94 co-authors. Here are the top co-authors by number of shared publications:

  • Santiago Borasino

    Division of Pediatric Cardiology, Section of Cardiac Critical Care, University of Alabama at Birmingham, Birmingham, AL, 35233, USA

    16 shared publications
  • Mark Aaron Law

    University of Alabama at Birmingham

    11 shared publications
  • Robert J. Dabal

    Department of Surgery; Division of Cardiothoracic Surgery; University of Alabama at Birmingham; Birmingham Ala USA

    7 shared publications
  • Joseph G. Timpa

    Department of Cardiovascular Perfusion, Childrens of Alabama, Birmingham, Alabama

    4 shared publications
  • Leslie A. Rhodes

    Pediatric Cardiology, Section of Cardiac Critical Care, University of Alabama at Birmingham, Birmingham, AL

    4 shared publications
  • William C. Sasser

    From: Division of Pediatric Critical Care Medicine, Section of Cardiac Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA

    4 shared publications

Latest Publications

  • Aspiration After Congenital Heart Surgery

    by James E. B. Raulston, Benjamin Smood, Ashley Moellinger, Ashley Heinemann, Nicholas Smith, Santiago Borasino, Mark A. Law, Jeffrey A. Alten

    Dysphagia and vocal cord dysfunction are frequent complications after congenital heart surgery. Both are risk factors for aspiration, which can lead to pneumonia, progressive lung disease, and respiratory arrest. A protocol was implemented to promote early detection of aspiration in a high-risk cohort of patients. Retrospective data were collected on all patients under 120 days old who underwent the Norwood procedure, aortic arch repair, Blalock–Taussig shunt placement, or cervical cannulation for extracorporeal membrane oxygenation from 10/2012 to 05/2016 at a single institution. Patients underwent an assessment of symptoms, fiberoptic endoscopic evaluation of swallowing (FEES), and modified barium swallow (MBS) study in the postoperative period prior to initiating oral feeds. Patients with and without aspiration were compared. Of the 96 patients included in the study, one-third (33%) of patients had evidence of vocal cord dysfunction by FEES and just over half (51%) had evidence of aspiration by FEES or MBS. Most (73%) of the patients with aspiration were asymptomatic and a majority (53%) of patients with aspiration had normal vocal cord function. Aspiration is common after congenital heart surgery, and an assessment of vocal cord or swallow function in isolation may lead to underdiagnosis. A comprehensive protocol including MBS and FEES is necessary for the early detection of vocal cord dysfunction and aspiration and may prevent adverse outcomes in high-risk postoperative patients.


  • Nutrition Considerations in the Pediatric Cardiac Intensive Care Unit Patient

    by Lindsey Justice, Jason R. Buckley, Alejandro Floh, Megan Horsley, Jeffrey Alten, Vijay Anand, Steven M. Schwartz

    Adequate caloric intake plays a vital role in the course of illness and the recovery of critically ill patients. Nutritional status and nutrient delivery during critical illness have been linked to clinical outcomes such as mortality, incidence of infection, and length of stay. However, feeding practices with critically ill pediatric patients after cardiac surgery are variable. The Pediatric Cardiac Intensive Care Society sought to provide an expert review on provision of nutrition to pediatric cardiac intensive care patients, including caloric requirements, practical considerations for providing nutrition, safety of enteral nutrition in controversial populations, feeding considerations with chylothorax, and the benefits of feeding beyond nutrition. This article addresses these areas of concern and controversy.


  • Open Access

    Correction to: Routine Sildenafil Does Not Improve Clinical Outcomes After Fontan Operation

    by J. Leslie Gaddis Collins, Mark A. Law, Santiago Borasino, W. Clinton Erwin, David C. Cleveland, Jeffrey A. Alten

    The original version of this article unfortunately contained a mistake. The presentation of Table 2 was incorrect .The corrected table is given below.


  • Routine Sildenafil Does Not Improve Clinical Outcomes After Fontan Operation

    by J. Leslie Gaddis Collins, Mark A. Law, Santiago Borasino, W. Clinton Erwin, David C. Cleveland, Jeffrey A. Alten

    Fontan operation can be complicated by persistent chest tube output (CTO) leading to prolonged hospital length of stay (LOS). Postoperative sildenafil administration has been shown to improve clinical outcomes in selected patients after Fontan. We initiated a practice change utilizing intravenous (IV) sildenafil in early postoperative period in all patients undergoing Fontan operation with aim to decrease LOS and CTO. Nineteen patients (February 2014–May 2016) received 0.35 mg/kg sildenafil IV (three doses) followed by enteral, 1 mg/kg every eight hours until hospital discharge. Clinical outcomes were compared to 84 pre-protocol controls. Vital signs were recorded after second sildenafil dose. Demographics were similar between groups. Sildenafil group had longer median LOS [9 (7, 11) vs. 13 (8, 25) days, p = 0.016]. CTO days were longer [6 (5, 8) vs. 8 (6, 13) days, p = 0.011]. Sildenafil group had longer mechanical ventilation [6.9 (3.5, 11.1) vs. 4 (2, 7) h, p = 0.045] and longer oxygen therapy [99 (52, 225) vs. 14.5 (14, 56) h, p = 0.001]. There was a trend towards more albumin 5% resuscitation in first 24 h [17 (1, 30) vs. 21 (10, 40) ml/kg, p = 0.069]. There was no difference in inotrope score at 24 h, maximum lactate, or fluid balance. Readmission rates were similar. There was no mortality. IV sildenafil was well tolerated, and no doses were held. Routine early administration of sildenafil after Fontan operation is not associated with an improvement in any measured clinical outcome, including postoperative CTO, LOS, colloid administration, or duration of mechanical ventilation.


  • The authors reply

    by Leslie A. Rhodes, Santiago Borasino, Jeffrey A. Alten

  • Kinetics of the cell cycle arrest biomarkers (TIMP-2*IGFBP-7) for prediction of acute kidney injury in infants after cardiac surgery

    by Katja M. Gist, Stuart L. Goldstein, Julia Wrona, Jeffrey A. Alten, Rajit K. Basu, David S. Cooper, Danielle E. Soranno, Jane Duplantis, Christopher Altmann, Zhiqian Gao, et al.

    Background Tissue inhibitor metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding protein-7 (IGFBP-7) are cell-cycle arrest biomarkers that have been shown to be predictive of acute kidney injury (AKI) in critically ill adults. AKI affects a large proportion (40%) of children following cardiac surgery. The aim of this study was to describe the kinetics of TIMP-2*IGFBP-7 and test its ability to predict AKI in infants following cardiac surgery. Methods A multicenter prospective study was performed in infants undergoing cardiac surgery with cardiopulmonary bypass (CPB) from October 2013 to January 2015. Urine samples were obtained at baseline and at 2, 6, 12, 24, 48 and 72 h after CPB initiation. TIMP-2*IGFBP-7 concentration was measured in urine samples using the Astute 140® meter to determine a risk score for AKI. This risk score is the product of TIMP-2 (ng/mL) and IGFBP-7 (ng/mL) divided by 1000. Results A total of 94 infants with a mean age of 154.2 ± 85.7 days were enrolled in the study, of whom 31 (33%) subsequently developed AKI. The mean time to AKI diagnosis was 25 ± 7 h after CPB initiation. The concentration of TIMP-2*IGFBP-7 was significantly higher in patients with AKI at 12 h after CPB initiation relative to baseline (p = 0.006). At 12 h after CPB initiation patients with a TIMP-2*IGFBP-7 concentration of ≥0.78 had a threefold higher odds of developing AKI than those with a TIMP-2*IGFBP-7 concentration of < 0.78 (95% confidence interval 1.47–6.11, p = 0.001). Conclusion These results demonstration that TIMP-2*IGFBP-7 concentration can be used in infants to predict subsequent serum creatinine-defined AKI following CPB.


  • Central Venous to Arterial Co 2 Difference After Cardiac Surgery in Infants and Neonates*

    by Leslie A. Rhodes, W. Clinton Erwin, Santiago Borasino, David C. Cleveland, Jeffrey A. Alten

    Objectives: Venous to arterial Co2difference correlates with cardiac output in critically ill adults, but its utility in pediatric patients is unclear. We sought to correlate venous to arterial Co2difference with other cardiac output surrogates (arteriovenous oxygen saturation difference, central venous oxygen saturation, and lactate) and investigate its capacity to predict poor outcomes associated with low cardiac output (low cardiac output syndrome) in infants after cardiac surgery with cardiopulmonary bypass.Design: Retrospective chart review. Poor outcome was defined as any inotrope score greater than 15; death, cardiac arrest, extracorporeal membrane oxygenation; and unplanned surgical reintervention.Setting: Pediatric cardiovascular ICU.Patients: One hundred thirty-nine infants less than 90 days who underwent cardiopulmonary bypass, from October 2012 to May 2015.Intervention: None.Measurements and Main Results: Two hundred ninety-six arterial and venous blood gas pairs from admission (n= 139), 6 (n= 62), 12 (n= 73), and 24 hours (n= 22) were included in analysis. For all pairs, venous to arterial Co2difference was moderately correlated with arteriovenous oxygen saturation difference (R2= 0.53;p< 0.01) and central venous oxygen saturation (R2= –0.43;p< 0.01), but not lactate. At admission, venous to arterial Co2difference was also moderately correlated with central venous oxygen saturation (R2= –0.40;p< 0.01) and arteriovenous oxygen saturation difference (R2= 0.55;p< 0.01), but not lactate. Thirty-four of 139 neonates (24.5%) had poor outcome. Median admission venous to arterial Co2difference was 5.9 mm Hg (3.8–9.2 mm Hg). Patients with poor outcome had median admission venous to arterial Co2difference 8.3 (5.6–14.9) versus 5.4 mm Hg (3.0–8.4 mm Hg) in those without poor outcome. Venous to arterial Co2difference (area under the curve = 0.69;p< 0.01), serum lactate (area under the curve = 0.64;p= 0.02), and central venous oxygen saturation (area under the curve = 0.74;p< 0.01) were predictive of poor outcome. After controlling for covariates, admission venous to arterial Co2difference remained significantly associated with poor outcome (odds ratio, 1.3; 95% CI, 1.1–1.45), including independent association with mortality (odds ratio, 1.2; 95% CI, 1.07–1.31).Conclusions: Venous to arterial Co2difference is correlated with important surrogates of cardiac output, and is associated with poor outcome and mortality related to low cardiac output syndrome after cardiac surgery in infants. Prospective validation of these findings, including confirmation that venous to arterial Co2difference can identify low cardiac output syndrome in real time, is warranted.


  • Defining Low Cardiac Output Syndrome: An Ode to Justice Potter Stewart*

    by Jeffrey A. Alten, Michael Gaies

    Read 'Defining Low Cardiac Output Syndrome: An Ode to Justice Potter Stewart.' on Ovid Insights


  • Adrenal insufficiency in neonates after cardiac surgery with cardiopulmonary bypass

    by Jack H. Crawford, Matthew S. Hull, Santiago Borasino, Brad L. Steenwyk, Kristal M. Hock, Kevin Wall, Jeffrey A. Alten

    Background: Cardiopulmonary bypass (CPB) may lead to adrenal insufficiency (AI). Emerging evidence supports association of AI with morbidity after cardiac surgery.Aims: The aim of this study was to define AI incidence in neonates undergoing complex cardiac surgery with CPB and its association with intraoperative post‐CPB outcomes.Methods: Forty subjects enrolled in a prior randomized control trial who received preoperative methylprednisolone as part of our institutional neonatal bypass protocol were included. No intraoperative steroids were given. ACTH stimulation tests were performed: preoperatively and 1 h after separation from CPB. AI was defined as −1 increase in cortisol at 30 min post cosyntropin 1 mcg. Clinical outcomes were collected up to 90 min after CPB.Results: 2/40 (5%) subjects had preoperative AI vs 13/40 (32.5%) post‐CPB AI, P ≤ 0.001. No significant difference was observed in age, gestational age, weight, CPB time, circulatory arrest, or STAT category between subjects with or without post‐CPB AI. ACTH decreased from preoperative values 127.3 vs 35 pcg·ml−1 [median difference = 81.8, 95% CI = 22.7–127.3], while cortisol increased from 18.9 vs 75 μg·dl−1 [median difference = 52.2, 95% CI = 36.3–70.9]. Post‐CPB AI was associated with increased median colloid resuscitation, 275 vs 119 ml·kg−1 [median difference = 97.8, 95% CI = 7.1–202.2]; higher median peak lactate, 9.4 vs 6.9 mg·dl−1 [median difference = 3.2, 95% CI = 0.04–6.7]; median post‐CPB lactate, 7.9 vs 4.3 mg·dl−1, [median difference 3.6, 95% CI = 2.1–4.7], and median lactate on admission to CICU, 9.4 vs 6.0 mg·dl−1 [median difference = 3, 95% CI = 1.1–4.9]. No difference was observed in blood pressure or vasoactive inotrope score at any time point measured in operating room (OR). Higher initial post‐CPB cortisol correlated with decreased cosyntropin response.Conclusions: Neonatal cardiac surgery with CPB and preoperative methylprednisolone leads to AI as determined by low‐dose ACTH stimulation test in one‐third of patients. AI is associated with increased serum lactate and colloid resuscitation in OR. Impact of preoperative methylprednisolone on results is not defined. Benefit of postoperative steroid administration in neonates with post‐CPB AI warrants further investigation.


  • Decreasing IV Potassium in Pediatric Cardiac Intensive Care

    by Leslie A. Rhodes, Kevin M. Wall, Staci L. Abernathy, Ashley B. Moellinger, Santiago Borasino, Jeffrey A. Alten

    IV potassium supplementation is commonly used in the pediatric cardiovascular ICU. However, concentrated IV potassium chloride doses can lead to life-threatening complications. We report results of a quality improvement project aimed at decreasing concentrated IV potassium chloride exposure. Retrospective evaluation of a quality improvement project aimed at reducing IV potassium chloride exposure. Pediatric cardiac ICU. All patients admitted to pediatric cardiac ICUs in April 2013 to September 2013 (preprotocol) and October 2013 to April 2014 (postprotocol). A quality improvement team developed a potassium protocol aimed at maintaining serum potassium levels 3.0–5.5 mEq/L, via algorithm focused on early enteral supplementation. All patients receiving IV diuretics who had a serum potassium level less than 4.5 mEq/L and urine output more than 0.5 mL/kg/hr had protocol initiated with potassium chloride–containing IV fluids or enteral potassium chloride. Concentrated IV potassium chloride infusions were limited to asymptomatic patients with serum potassium less than 2.0 mEq/L and high-risk patients at less than 3.0 mEq/L. Serum potassium levels were measured once daily, and protocolized adjustments were made based on this level and concurrent diuretic therapy. Serum potassium, potassium chloride supplementation, patient cost, fluid administration, and arrhythmia incidence were compared pre and post protocol. Four hundred forty-three admissions were included (234 pre protocol and 209 post protocol). No significant differences were found in demographics. There was no difference in mean morning serum potassium after protocol implementation (3.85 [0.77] mEq/L before protocol and 3.89 [0.75] mEq/L after protocol; p = 0.90). Concentrated IV potassium chloride administration was decreased by 86% (331 vs 47 doses). With protocol, there was decreased incidence in days with one measured episode of hyperkalemia (11 vs 4/1,000 patient-days; p = 0.02) and a trend toward decreased hypokalemia (433 vs 400/1,000 patient-days; p = 0.05). Arrhythmia incidence was similar (p = 0.59). Protocolized potassium management in pediatric cardiac intensive care patients decreased concentrated IV potassium chloride exposure and incidence of hyperkalemia. Lower potassium treatment threshold for IV potassium chloride was not associated with increased arrhythmias.